What Connect Biopharma does

Connect Biopharma Holdings Limited (NASDAQ: CNTB) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with operations in the U.S. and China (Taicang R&D facility). The company is focused on developing next-generation antibody therapies for inflammatory diseases, principally type-2 inflammation-driven conditions including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.

The company's lead product candidate is rademikibart (formerly CBP-201), a next-generation monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα). By blocking IL-4Rα, rademikibart inhibits both IL-4 and IL-13 signaling, the central drivers of type-2 inflammation. It has demonstrated clinical activity in both atopic dermatitis (Phase 2b completed; partner Simcere has completed a Phase 3 in China with an NDA pending) and asthma (global Phase 2b completed), and Phase 1 data showed rapid FEV1 improvements of 100–400 mL as early as 15 minutes post-dosing, a profile that positions the asset for the acute exacerbation setting rather than purely chronic maintenance. A second pipeline candidate, icanbelimod (CBP-307), is in development for ulcerative colitis.

Connect Biopharma is pre-revenue (Q1 2026 revenue approximately ($0.05 million)) and monetizes today primarily through licensing. It holds an exclusive Greater China license with Simcere Pharmaceutical — worth up to $110 million in potential milestones plus tiered royalties on net sales — and is seeking a commercial partner for broader inflammatory disease commercialization. The company funded operations into the second half of 2027 following a $20.2 million private placement in March 2026 led by Panacea Venture. Estimated hospital pricing for rademikibart of $600–$700 per dose compares with Dupixent's approximately $3,800 per month, signaling a potential cost-advantage thesis at launch. Go-to-market activities center on investor conferences, medical conference presentations, and disease-awareness partnerships ahead of any U.S. approval.

Name

Connect Biopharma

Legal name

Connect Biopharma Holdings Limited

Website

https://connectbiopharma.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Connect Biopharma (NASDAQ: CNTB) is a clinical-stage biopharmaceutical company developing rademikibart, a next-generation anti-IL-4Rα antibody for acute asthma and COPD exacerbations and atopic dermatitis, with a secondary candidate icanbelimod for ulcerative colitis. It monetizes via an exclusive Greater China license to Simcere Pharmaceutical while seeking a broader commercial partner.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Inflammatory disease therapeutics
• Biopharmaceutical drug development
• Monoclonal antibody therapies
• Asthma COPD treatments
• Atopic dermatitis biologics

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharma company developing rademikibart for asthma, COPD, and atopic dermatitis. Expected to fund operations into second half of 2027 with current cash reserves.
2. Licensing Revenue - Simcere Partnership: Exclusive license agreement with Simcere Pharmaceutical for rademikibart in Greater China with potential milestone payments of up to $110 million plus tiered royalties on net sales. Simcere has an NDA pending with potential H2 approval triggering milestone payments.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Connect Biopharma is a clinical-stage biopharmaceutical company developing rademikibart, a next-generation anti-IL-4Rα antibody designed to treat acute asthma and COPD exacerbations as well as atopic dermatitis. The company also has icanbelimod (CBP-307) in its pipeline for ulcerative colitis. It licenses rademikibart to Simcere Pharmaceutical for Greater China and is pre-revenue.

Product overview

Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. The company's lead product candidate is rademikibart (formerly CBP-201), a next-generation antibody targeting interleukin-4 receptor alpha (IL-4Rα). The company is also developing icanbelimod (CBP-307) for ulcerative colitis. Connect Biopharma operates with global operations spanning the U.S. and China, and maintains an exclusive license agreement with Simcere Pharmaceutical for rademikibart in Greater China.

Differentiator

Problem solved

Functional benefit

Products and services

• Rademikibart (CBP-201) A next-generation anti-IL-4Rα antibody targeting interleukin-4 receptor alpha to treat acute asthma and COPD exacerbations and atopic dermatitis, intended for healthcare providers and biopharma licensees.
• Icanbelimod (CBP-307) An investigational therapy being evaluated for ulcerative colitis treatment as part of Connect Biopharma's pipeline of inflammatory disease treatments.

Quantifiable outcome

• Rapid FEV1 improvements of 100-400 mL as early as 15 minutes post-dosing maintained through Day 29 in Phase 1 study
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered minor and core.

• Jovante Woods FoundationminorStrategic or Co-development Partner · 13 April 2026Corporate partnership with the Jovante Woods Foundation (founded by NFL legend Ickey Woods) to accelerate asthma testing and educational programs for children nationwide through the 'Score 6 for 24' fundraising campaign.
• Simcere PharmaceuticalcoreOEM/ Whitelabel/ Licensing Partner · 30 March 2026Exclusive license agreement with Simcere Pharmaceutical for rademikibart in Greater China worth up to $110 million in potential milestone payments plus tiered royalties on net sales. Simcere conducted Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis in China, with NDA pending and potential H2 2026 approval triggering milestone payments.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AstraZeneca: Markets Tezspire (tezepelumab) and Fasenra (benralizumab) in severe asthma and has expanded respiratory biologic offerings, making it a direct competitor in the type 2 inflammation and severe asthma segments where rademikibart is positioned.
• Sanofi: Commercializes Dupixent alongside Regeneron and is the dominant player in the atopic dermatitis and asthma biologic markets rademikibart is targeting. Highly comparable as the established incumbent in the same disease areas with overlapping IL-4Rα positioning.
• Galderma: Markets Nemluvio (nemolizumab) for atopic dermatitis and prurigo nodularis, directly competing with rademikibart's atopic dermatitis indication. Comparable as a dermatology-focused immunology biologic peer.
• Amgen: Co-developer of Tezspire (tezepelumab) with AstraZeneca for severe asthma, directly competing with rademikibart's planned acute asthma positioning and overlapping with rademikibart's type 2 inflammation focus.
• Novartis: Markets Xolair (omalizumab) for allergic asthma and other inflammatory indications, competing in the same physician-prescribed biologic asthma space that rademikibart targets with its anti-IL-4Rα approach.
• GSK (GlaxoSmithKline): Markets Nucala (mepolizumab) and Trelegy in asthma and COPD, and has a substantial respiratory biologic franchise overlapping with rademikibart's lead indications. Directly comparable as an established respiratory immunology competitor.
• Regeneron Pharmaceuticals: Co-developer of Dupixent (dupilumab), the leading IL-4Rα antibody and the direct therapeutic competitor to rademikibart in asthma, COPD, and atopic dermatitis. Most directly comparable peer given identical mechanism and overlapping indications.

Broad incumbents

• Pfizer: Markets Cibinqo (abrocitinib) and Eucrisa in atopic dermatitis, as well as broader respiratory and inflammation assets. Comparable as a broad incumbent in the inflammatory dermatology and respiratory disease categories overlapping with rademikibart's indications.
• Eli Lilly: Markets Olumiant (baricitinib, JAK inhibitor) and Taltz in inflammatory diseases including atopic dermatitis and asthma-adjacent indications. Comparable as a broad incumbent in the inflammatory disease space where rademikibart competes.

Emerging players

• Arcutis Biotherapeutics: Commercial-stage dermatology company developing topical and biologic therapies for inflammatory skin diseases including atopic dermatitis. Comparable as an emerging immunology/dermatology player with overlapping addressable market, though smaller and focused on topicals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/connect-biopharmaceuticals-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Connect Biopharma